Insmed Target Price

Analysts' average 12-month price target for Insmed is $190.

Get informed when a big investor buys or sells

+ Follow

Share Price

$111.12

Average Target Price

$193.13

73.8% upside

15 analysts in the last 4 months

High: $235 | Low: $161

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-09-30	Barclays	$207	86.3% upside
2026-09-24	Goldman Sachs	$188	69.2% upside
2026-09-15	Roth CapitalAdam Walsh	$198	78.2% upside
2026-08-10	Truist Financial	$195	75.5% upside
2026-08-07	UBS	$172	54.8% upside
2026-08-07	Wells Fargo	$169	52.1% upside
2026-08-07	Evercore ISI	$170	53% upside
2026-08-07	Guggenheim	$205	84.5% upside
2026-08-07	Morgan Stanley	$218	96.2% upside
2026-08-06	Jefferies	$175	57.5% upside
2026-07-28	Cantor FitzgeraldOlivia Brayer	$235	111.5% upside
2026-07-20	H.C. WainwrightAndrew Fein	$220	98% upside
2026-07-20	BMO CapitalConor MacKay	$192	72.8% upside
2026-07-15	Wells Fargo	$161	44.9% upside
2026-06-16	Mizuho SecuritiesGraig Suvannavejh	$192	72.8% upside
2026-05-13	Truist Financial	$185	66.5% upside
2026-05-08	Wells Fargo	$160	44% upside
2026-05-08	GuggenheimVamil Divan	$226	103.4% upside
2026-04-16	Guggenheim	$230	107% upside
2026-04-14	RBC Capital	$216	94.4% upside
2026-04-10	Raymond James	$200	80% upside
2026-04-08	Mizuho Securities	$202	81.8% upside
2026-03-26	H.C. Wainwright	$245	120.5% upside
2026-02-24	Mizuho Securities	$204	83.6% upside
2026-02-20	Wells FargoTiago Fauth	$208	87.2% upside
2026-02-20	Morgan Stanley	$166	49.4% upside
2026-02-19	Mizuho SecuritiesGraig Suvannavejh	$211	89.9% upside
2026-02-19	Stifel Nicolaus	$205	84.5% upside
2026-01-27	BarclaysEliana Merle	$231	107.9% upside
2026-01-22	Roth Capital	$212	90.8% upside
2026-01-21	RBC CapitalLeonid Timashev	$200	80% upside
2026-01-12	Truist FinancialDanielle Brill	$205	84.5% upside
2026-01-08	Morgan StanleyMaxwell Skor	$157	41.3% upside
2026-01-06	UBS	$215	93.5% upside
2025-12-19	Truist FinancialDanielle Brill	$202	81.8% upside
2025-12-18	Cowen & Co.	$241	116.9% upside
2025-12-18	H.C. Wainwright	$230	107% upside
2025-12-18	Wolfe ResearchAndy Chen	$167	50.3% upside
2025-12-18	Wells Fargo	$195	75.5% upside
2025-12-18	RBC CapitalLeonid Timashev	$195	75.5% upside
2025-12-18	Wedbush	$203	82.7% upside
2025-12-18	Guggenheim	$221	98.9% upside
2025-12-18	Mizuho SecuritiesGraig Suvannavejh	$212	90.8% upside
2025-12-16	Wells FargoTiago Fauth	$234	110.6% upside
2025-12-16	Cantor FitzgeraldOlivia Brayer	$230	107% upside
2025-12-10	Jefferies	$269	142.1% upside
2025-12-04	Redburn Partners	$263	136.7% upside
2025-12-01	Mizuho SecuritiesGraig Suvannavejh	$256	130.4% upside
2025-10-31	UBSTrung Huynh	$223	100.7% upside
2025-10-31	Wells Fargo	$217	95.3% upside

Insmed (INSM) FAQ

Insmed (INSM) currently reports a target price of $190. Use the charts on this page to explore Insmed's target price history and peer comparisons.

Analysts' average 12-month price target for Insmed is $190, about 73.8% upside from the current share price of $111.12. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $190, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Insmed, and consider following INSM for alerts when major investors trade the stock.

Insmed is classified in the Healthcare sector. On target price, it currently shows $190. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing INSM with unrelated industries.